Latest Breaking News On - Centogene gmbh - Page 1 : comparemela.com

CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study March 09, 2021 06:30 ET | Source: CENTOGENE GmbH CENTOGENE GmbH Rostock, GERMANY Rostock International Parkinson s Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment Significant milestone of 10,000 participants reached With over 120 study sites around the world, CENTOGENE is leading the largest corresponding study for genetics in Parkinson’s disease ever performed CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a significant milestone in its Rostock International Parkinson

Peter bauerUnited statesUnited kingdomLawlor oboyleMovement disordersExchange commissionBen legg corporate communicationsInternational parkinson disease projectDrug administrationRostock international parkinson disease studyRostock international parkinson diseaseInternational parkinsonRostock international parkinsonChief genomic officerDenali therapeuticsDisease study